Skip to content
Open access

Effects of an optimized beta-glucan–based formulation on symptoms, functional capacity, and systemic inflammation in patients with COPD: a randomized controlled trial

Nov 2026 · Frontiers in Pharmacology · 0 citations · 61 references

Abstract

Chronic obstructive pulmonary disease (COPD) is characterized by persistent airflow limitation, chronic inflammation, and oxidative stress, leading to progressive functional impairment and reduced quality of life. Beta-glucan possesses immunomodulatory and anti-inflammatory properties, but its therapeutic potential in COPD remains poorly defined. This study aimed to optimize a combined formulation of beta-glucan, broccoli extract, and quercetin (Pro β-Glucan+) through in vitro evaluation and to investigate its clinical efficacy in patients with stable COPD. HFL1 lung fibroblasts were treated with different ratios of Pro β-Glucan+®, and cell viability and wound healing assays were performed to identify the optimal formulation. The selected ratio was evaluated in a 12-week randomized, double-blind, placebo-controlled trial. A total of 42 participants were randomized, of whom 38 completed the study and were included in the final analysis (Pro β-Glucan+, n = 19; placebo, n = 19). Prespecified primary outcome was FEV 1 . Secondary outcomes included clinical symptoms, functional capacity, health status, inflammatory and oxidative stress biomarkers, and patient satisfaction. The 10:3:2 ratio (beta-glucan:broccoli extract:quercetin) significantly enhanced HFL1 cell cell viability and wound healing activity among the tested formulations and was selected for clinical evaluation. Pro β-Glucan+® was well tolerated and associated with within-group improvements in dyspnea, respiratory symptoms, functional capacity, and health status after 12 weeks, with significant between-group differences in mMRC and CAT scores at week 12. No significant within- or between-group difference was observed in the prespecified primary outcome, FEV 1 , or in systemic inflammatory and oxidative stress biomarkers. Patient satisfaction was higher with Pro β-Glucan+® than with placebo. The optimized Pro β-Glucan+® formulation demonstrated in vitro biological activity and was associated with improvements in several clinical outcomes in patients with stable COPD. Significant between-group differences were observed in mMRC and CAT scores at week 12. These findings support further investigation of this combination as an adjunctive nutritional intervention for COPD management. https://clinicaltrials.gov/study/NCT05878834 , identifier NCT05878834.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.